We use cookies to enhance your experience. If you continue browsing, it means you agree to our use of these cookies. For detailed information on how we use cookies, please refer to our cookie policy.
Aurisco Pharmaceutical Co., Ltd. (SH.605116), established in 1998, is an innovative and international pharmaceutical company specializing in the R&D, production, and sales of specialized complex APIs and finished dosage forms. The company operates with its headquarters in Shanghai, featuring four production facilities and five R&D centers, along with sales branches in the United States, Europe, India, and South America.
With over two decades of deep commitment in the pharmaceutical industry, Aurisco continuously drives technological innovation and has achieved a leading position in China in areas such as complex synthesis, synthetic biology, and photochemistry. The company has established long-term partnerships with renowned global pharmaceutical enterprises.
Supported by a robust quality and EHS management system, sufficient production capacity, and a global sales network, Aurisco provides high-quality products and efficient services to customers worldwide.
Aurisco founded
Shanghai Operation Center established
Yangzhou Lian'ao Established Primarily For Fermentation Research And Production
Tiantai Badu Facility and Yangzhou Facility Put Into Use
FDA Approval of Tiantai Facility
Yangzhou Aurisco Established
Aurisco Pharmaceutical (Joint Stock) Co., Ltd. Established
APTI Tianjin R&D Center by acquiring R&D center of Apotex Tianjin
Listed on the Shanghai Stock Exchange
Shanghai Aurisco Biotechnology Co., Ltd. Established
Aoxintong (Dydrogesterone 10mg, the first finished dosage form) Approval in China
Tiantai Cangshan Put Into Use